Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? - Wikidata - awgldk - TriplyDB

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

http://www.wikidata.org/entity/Q37948672

about

Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane Industrial natural product chemistry for drug discovery and development.Long response to eribulin in breast cancer: a case report.

P2860

Q37177111-ADA920F5-C60A-463A-882A-2E8860D65C7C Q38154186-49EB6414-422B-492E-ABB2-0444048F3D2E Q38978452-40CC4B9B-0AFC-4339-A669-209C1D8671EE

P2860

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

http://www.wikidata.org/entity/Q37948672

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Survival benefit of eribulin m ...... atic breast cancer: what next?

@en

Survival benefit of eribulin m ...... atic breast cancer: what next?

@nl

type

label

Survival benefit of eribulin m ...... atic breast cancer: what next?

@en

Survival benefit of eribulin m ...... atic breast cancer: what next?

@nl

prefLabel

Survival benefit of eribulin m ...... atic breast cancer: what next?

@en

Survival benefit of eribulin m ...... atic breast cancer: what next?

@nl

P1433

Q37948672-B116D8E9-087D-48AC-AA6C-E39BEE503259

P1476

Q37948672-C0215299-3FE0-45F8-88D7-8100415946F8

P2093

Q37948672-3937CF5A-163F-44A9-A8F2-F4F9C86D1929

Q37948672-4254A9AF-A38F-4CC1-9B87-DB56990B9695

P2860

Q37948672-091FA483-1CB4-4E75-A0AE-F352ED57C8A7

Q37948672-0B186B42-6972-4B59-B35F-8B9D9D02A80E

Q37948672-1A6D0AE2-DD94-4E9A-9B44-0D728C8B46E6

Q37948672-46992F51-BDC9-4616-9DD5-C63DDF091EA4

Q37948672-6546D5B8-AB6A-4E3C-8F4A-1D11B04CD25E

Q37948672-686F814A-DEAE-4985-8D52-1AF65F2FC1E4

Q37948672-84B80611-64EA-4970-8F49-07AC0267B91D

Q37948672-934705D1-DD37-4DDF-8A92-0BE921145A56

Q37948672-9F2F7BC3-38CC-403A-8CBD-4EE98D545BEF

Q37948672-A508BC7F-C631-4473-867B-7A70C43D6A2B

P2888

Q37948672-DB893F4C-663B-4E9C-9DB6-2E214432538E

P304

Q37948672-EA9DDF23-418D-4816-A55C-6EB6AA7B5F66

P31

Q37948672-53C90426-312B-4669-AEF2-5FE54EE1417F

P356

Q37948672-CD8EA7FC-24EA-41F2-B2EA-95C5C46ACE25

P407

Q37948672-A06B6C2A-994A-47F2-A70F-493FD4D45C1F

P433

Q37948672-31F82F9C-79DE-4810-8955-52F6FC5E6DA8

P478

Q37948672-E00F2A81-DA5B-413E-942D-0A8B81F45A04

P577

Q37948672-6FD03E88-2384-4131-96D6-74059D03EE7F

P698

Q37948672-12C573D3-F277-40A5-8AF7-61156627E503

P356

S12325-011-0070-9

P1433

Advances in Therapy

P1476

Survival benefit of eribulin m ...... atic breast cancer: what next?

@en

P2093

Ahmad Awada

http://www.w3.org/2001/XMLSchema#string

Philippe Aftimos

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

Estimates of the cancer incidence and mortality in Europe in 2006.

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

Facts and controversies in systemic treatment of metastatic breast cancer.

P2888

s12325-011-0070-9

P304

973-985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-011-0070-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22020735

http://www.w3.org/2001/XMLSchema#string